R&D Systems. CD34 Antibodies For Canine, Porcine, Human, Mouse & Rat Reactivity. Monoclonal CD34 Antibodies.Validated in FLOW, ICC/IF, WB, CyTOF. Quality Guaranteed Cryopreserved and Ready-to-Use Human Cord Blood CD34+ Cells. Contact us for donor information or to request a quote CD34 is an antigen present in hematopoietic progenitor cells and endothelial cells. Anti-CD34 antibody is a highly sensitive marker for endothelial cell differentiation and has also been studied as a marker for vascular tumors. However, there are few studies relating it to cervical carcinoma CD34 is expressed by LYVE-1 (+)/podoplanin (+)/Prox1 (+) tumor-associated LECs in colon, breast, lung, and skin tumors. More than 60% of analyzed tumors contained detectable intratumoral lymphatics. Of these, more than 80% showed complete co-localization of CD34 with LEC markers
Expression of CD34 on cancer associated fibroblasts (CAFs) is an independent prognostic factor in stage I-III NSCLC. SMA+ cancer associated fibroblasts are associated with higher tumor stages in NSCLC and might contribute to tumor progression in NSCLC Microvascularity or neovascularity as measured by the CD34 antigen may be a prognostic marker of recurrence for prostate cancer patients after radical prostatectomy but more study in prostate specific antigen era patients with sufficient followup is needed
Distinguish CD34+ dermal neoplasms such as Kaposi's sarcoma, dermatofibrosarcoma protuberans / DSFP (both CD34+) and epithelioid sarcoma (often CD34+) from dematofibroma (CD34-) Distinguish solitary fibrous tumor (CD34+) from desmoplastic mesothelioma (CD34-) (Hum Pathol 1995;26:428 Several origins have been proposed for cancer-associated fibroblasts (CAFs), including resident CD34+ stromal cells/telocytes (CD34+SCs/TCs). The characteristics and arrangement of mammary CD34+SCs/TCs are well known and invasive lobular carcinoma of the breast (ILC) is one of the few malignant epithelial tumours with stromal cells that can express CD34 or αSMA, which could facilitate. RATIONALE: Intracranial solitary fibrous tumor (ISFT) is a rare spindle cell tumor derived from dendritic mesenchymal cells expressing CD34 antigens, which are widely distributed in human connective tissues. PATIENT CONCERNS: In two case reports, we describe a 61-year-old woman and a 42-year-old man who present with intracranial malignant SFTs.. Computed tomography or magnetic resonance.
Acute Myelogenous Leukemia CD34+ /CD38 − is the earliest documented CSC marker expression pattern identified by Dick et al. in 1994. These markers are still widely used to identify acute myelogenous leukemia (AML) CSCs. CD34 + /CD38 − cells were capable of repopulating AML in SCID mice CD34 derives its name from the cluster of differentiation protocol that identifies cell surface antigens. CD34 was first described on hematopoietic stem cells independently by Civin et al. and Tindle et al. as a cell surface glycoprotein and functions as a cell-cell adhesion factor
CD34 and CD38 proteins are usually used as surface markers to identify HSCs and Leukemic stem cells. However, there have been cases that lacked CD34 or CD38 protein but still had leukemia initiating capacity in B-ALL suggesting the restrictive of these two markers In humans CD34 is a valid and reliable marker for hematopoletic stem and progenitor cells. In general, solid tumors, with the exception of endothelial cancers, do not express CD34. Accordingly, immunological selection of CD34 + hematopoietic stem/progenitor cells can be used to remove CD34 - malignant cells in the setting of autotransplantation Solitary fibrous tumors and Kaposi's sarcomas, which are typically CD34 positive, were consistently CD117 negative. Among the CD34-positive tumors that showed occasional CD117 reactivity were dermatofibrosarcoma protuberans (1 of 7) and hemangiopericytoma (2 of 10)
. because it has a greater affinity for activated endothelial cells, whereas CD34 and CD31 can react with both normal vessels and activated vessels CD34 is a marker of hematopoietic stem cells. CD13 and CD33 are myeloid antigens. CD19 is expressed by both mature and immature B cells and CD10 is expressed during the early stages of B-cell differentiation. CD80 (also known as BB1/B7-1), CD86 (also known as B70/B7-2), and CD40 are accessory and costimulatory molecules Current research has focused CD34 as a prognostic indicator in tumors. In a recent study, investigators reported that CD34 expression is significantly lower in malignant tumors compared to their benign counterparts (2). CD34 is also used to distinguish between different subtypes of a particular cancer such as acute leukemia (3) Tumor lymphatics are now widely recognized to play a critical and rate-limiting role for metastatic tumor spread.13, 33 Correspondingly, the detection of intratumoral lymphatics using pan-LEC markers has been correlated with tumor progression and metastasis.8, 34, 35 The identification of CD34 as the first marker to selectively identify tumor.
Furthermore, CLEC12A has been proposed as a possi- using flow cytometry is a growing field of interest and highly ble marker for LSC as it can be found on CD34+CD38 cells sensitive multicolour immunophenotypic profiling and in CD34-positive AML, but is completely absent on the accompanying scoring systems have proven useful in MDS, CD34+CD38. CD34 is known as an optimum marker for microvascular density studies and it is positively stained in pathological and physiologic vessels. The use of CD34 for the prognosis, diagnosis, and treatment of neoplasms has been increasingly discussed Among the spindle cell neoplasms, CD34 + lesions constitute a unique heterogeneous group spanning from fibrohistiocytic, adipose, neural, and vascular neoplasms. 1 Most of the diagnostic challenges are within the fibroblastic/fibrohistiocytic/myofibroblastic lineage CONCLUSION: The results suggest that nestin might be a reliable marker for angiogenesis evaluation in patients with colorectal cancer. In contrast to CD34, the expression of nestin in blood vessels seems to be a more sensitive marker of cancer progression
The expression of cell surface antigens is frequently employed as cancer stem cells (CSC) markers. Lipoma-derived stem cells may originate from hASCs and we ascertained the expression of CD34, CD90, CD44 and CD54, all expressed on hASCs [ 2, 3, 5 ]. The CD90 exhibition has not been related to sarcoma CSCs in contrast to CD133 marker In addition to vascular tumors, CD34 is consistently expressed in solitary fibrous tumor, dermatofibrosarcoma protuberans, and spindle cell lipoma as well as a proportion of GISTs, epithelioid sarcomas, and MPNSTs, to name a few notable tumor types (Box 1.3) Product overview. Endothelial Cell Marker (CD31, CD34, ICAM1, CD45) Antibody Sampler Panel - Human ab254023 contains multiple trial-sized versions of anti-human antibody clones against CD31, CD34, ICAM1, CD45, specifically selected for high performance in various applications. This panel contains 4 recombinant rabbit monoclonal antibodies. . CD31 is normally found on endothelial cells, platelets, macrophages and Kupffer cells, granulocytes, T / NK cells, lymphocytes, megakaryocytes, osteoclasts, neutrophils. In immunohistochemistry, CD31 is used primarily to demonstrate the presence.
The cell surface marker CD34 marks mouse hair follicle bulge cells, which have attributes of stem cells, including quiescence and multipotency. Using a CD34 knockout (KO) mouse, we tested the hypothesis that CD34 may participate in tumor development in mice because hair follicle stem cells are thought to be a major target of carcinogens in the two-stage model of mouse skin carcinogenesis Persistence of CD34 Stem Marker in Human Lipoma: Searching for Cancer Stem Cells Barbara Zavan2*, Francesco De Francesco1* , Francesco D'Andrea1, Letizia Ferroni 2, Chiara Gardin , Rosa Salzillo 1, Gianfranco Nicoletti , Giuseppe A. Ferraro 1
Tumor cell CD34 staining was membranous and/or cytoplasmic It is a possible limitation to the use of CD34 as a prognostic marker. In a wide resection specimen, to perform immunohistochemistry. Prostate cancer is the second cause of cancer-related deaths in men and this is attributed to its aggressiveness and metastatic identity. Our objective was to evaluate the expression patterns of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma (PCa) compared to benign prostate tissue and their relation to the clinicopathological features tumor size, localization and depth of inﬁltration (pT stage). Conclusions: CD34 was identiﬁed as an independent prognostic marker in pTNM stage I-III NSCLC. Moreover, loss of CD34+ CAFs might in ﬂuence the dedifferentia-tion of the NSCLC tumor from its cell origin. Finally, SMA+ CAFs are more preva
CD34 + keratocytes have been shown to express the epithelial cell marker CK3 96, and CD34 + cells from human fetal liver express biliary epithelial markers CK7, CK8, and CK18 97. CD34 and Endothelial Cells. CD34 is widely regarded as a marker of vascular endothelial progenitor cells 1, 98 To define marker- and target expression profiles in LSC, CD34 + /CD38 − CMML cells and CD34 + /CD38 + progenitor cells were analyzed by flow cytometry using a larger panel of mAb The expression of CD34 is associated with having a strong and durable proliferative capacity. Since CD34 stem cells have been considered hematopoietic only for many years, CD34 antigen has been used extensively as a marker for hematopoietic stem and progenitor cells. So much so that researchers working with mesenchymal stromal cells believed. Immunohistochemistry and antibodies against the endothelial cell markers CD31, CD34, and CD105 have frequently been used in previous studies of cancer tissues. There are many reports that have used these antibodies to investigate the pathological significance of MVD in prostate cancer tissues 2 - 4
51. Nassif AE, Tambara Filho R. Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Rev Col Bras Cir. 2010;37:338-44 52. Grosse-Gehling P, Fargeas CA, Dittfeld C. et al of CD34 and Examination of Prognostic Indicators Including Proliferation Markers Ki67 and AgNOR V. Gillespie1, K. Baer, J. Farrelly2, D. Craft3, and R. Luong4 Abstract Gastrointestinal stromal tumors (GISTs), leiomyomas, and leiomyosarcomas are common mesenchymal neoplasms in the gastrointestinal (GI) tract of dogs The endothelial cell marker CD34 has been found to be negative in normal hepatic sinusoids and diffusely positive in HCC due to capillarization of sinusoidal cells with loss of fenestrae in HCC. The present study was undertaken to evaluate the diagnostic utility of HepPar-1, CD10, and CD34 in differentiating HCC from metastatic carcinoma in. Moreover, CD34+ cells secrete VEGF, PDGF and IL-8, which promote angiogenesis 28, 29 and support postnatal neovascularization 5, 30. CD34+ cells, in lipoma, participate in tumor stroma formation and progression (in this case, also alphaSMA+). In lipoma, these cells are present in all or most cells, thereby contributing significantly to diagnosis The transmembrane phosphoglycoprotein protein CD34 has conventionally been regarded as a marker for hematopoietic progenitors. Its expression on these cells has been leveraged for cell therapy applications in various hematological disorders. More recently, the expression of CD34 has also been reported on cells of nonhematopoietic origin
CD45 dim CD34 + CD38 − CD133 + cells are present in high numbers in the bone marrow of patients with acute myeloid leukemia. The work flow of the four-color flow cytometry experiments using monoclonal antibodies (mAbs) is shown in Fig. 1.As shown in Fig. 1a and b, live BMCs were collected and SSC low /CD45 dim cells were obtained. The BMCs were stained with various combinations of monoclonal. the superiority of CD105 over CD34 as a marker of neoan- giogenesis in NHL, which is consist ent with studies of breast cancer, lung cancer , and hepatocellular carcinoma. 27 , 28 ,3 . Furthermore, a highly enriched CD34 negative stem cell fraction termed side population, could also express P-gp and particularly BCRP as a marker of an earlier progenitor cell [39,40]. Similarly, in normal brain, CD34 occurs onl
Comparative Study on the Immunohistochemical Expression of Maspin and CD34 in Normal Oral Mucosa, Ameloblastoma and Ameloblastic Carcinoma. Download. Related Papers. Expression of CD34 and Maspin in ameloblastoma from a West African subpopulation. By Charles Kirkpatrick and S. Udeabor CD31, also known as platelet endothelial cell adhesion molecule 1 (PECAM-1), is thought to be a sensitive and specific marker for vascular differentiation. 1, 2 It is a transmembrane glycoprotein expressed by endothelial cells and a variety of hematopoietic cells. 3 It is often used alone or in conjunction with CD34 in the diagnosis of vascular tumors, such as angiosarcomas. 4-7 It has.
cancer, urinary tract cancer CD34 Hemangiopericytoma solitary fibrous tumor, pleomorphic lipoma< gastrointestinal stromal tumor, derma 1 ofibrosarcoma procuburans CDH7 Chromogranin Cytoker.iiin (various types) Desmin Gastrointestinal stromal tumor, mastocytosis« seminoma Neuroendocrine lumor Many types of cat cinoma, some lypes ol sarcoma Smooth muscle sarcoma, skeletal muscle sarcoma. CD31. Platelet endothelial cell adhesion molecule (PECAM-1) also known as cluster of differentiation 31 (CD31) is a protein that in humans is encoded by the PECAM1 gene found on chromosome17q23.3. PECAM-1 plays a key role in removing aged neutrophils from the body
Surface glycoprotein CD34 is one of the markers of stemness in mouse hematopoietic progenitors. We hypothesized that among ascites cells there is a subpopulation of stem-like CD34+ cells. FACS analysis showed that this was indeed the case and that up to 7.0% of ascites tumor cells expressed CD34 marker (Fig. 2A, 2) The clinicopathological features of the 18 cases of superficial CD34-positive fibroblastic tumor are summarized in Table 1.The lesions occurred exclusively in adults (median age 38 years, range 20. gressive tumor-host interaction is the result of the de-structive tumor growth and remodelling, probably rep-resenting a form of survival mechanism that provides for the nutrient exchange. Related to the vasculogenic mimicry, and to the gain of an endothelial phenotype, is the CD31 and CD34 expression by tumor cells. CD31 (PECAM-1 is a marker of a unique subset of spindle cell tumors. In addition to vascular tumors, CD34 is expressed in dermatofibrosarcoma protuberans, solitary fibrous tumor/hemangiopericytoma, and a subset of nerve sheath tumors, among others. is a highly sensitive and specific marker for synovial sarcoma Hematopoietic stem cells (HSCs) are often identified with CD34, although this marker is also found on other progenitor cell types such as multipotent mesenchymal stromal cells (MSCs). A common way to stain for these leukemic stem cells is the aberrant expression of CD117 (Figure 5), also called proto-oncogene c-Kit or stem cell growth factor.
Apart from the well-known endothelial cell markers, CD34 and vWF, the expression of the other genes identified in both clusters have not been studied in HCC. Cell surface tumor endothelial. The expression level of CD34 and VEGFR2 showed no correlation to sunitinib response. In sorafenib treated patients, no association with ELTD1 expression and PFS/OS was found. Our results identify tumor vessel ELTD1 expression as a positive predictive marker for sunitinib-treatment in patients suffering from mRCC The roles of CD34 and Ki67 in tumor invasiveness have been confirmed immunohistochemically in several types of cancer cells, including breast cancer , gastric tumors and cervical cancer . CD34 and Ki67 are the highly sensitive markers for endothelial cell differentiation and have also been studied as markers for tumor invasiveness Purpose: Angiogenesis is an essential process in the progression of malignant tumors. Whereas pan-endothelial markers, such as CD34, are generally used in evaluation of angiogenesis, pan-endothelial antibodies react with not only newly forming vessels but also normal vessels just trapped within tumor tissues. It has been recently reported that anti-CD105 antibody preferentially reacts. These include 7 of 36 (19%) mice engrafted with CD34+CD19− cells, 33 of 72 (46%) mice engrafted with CD34+CD19+ cells and 20 of 53 (38%) mice engrafted with CD34−CD19+ cells. With as few as 2 × 10 3 CD34+CD19− cells being sufficient to re-initiate the leukemia, this intrafemoral ALL-NOD/ scid mouse model represents a very sensitive.
A, liver metastasis was double stained for CD34 as a vascular endothelial cell marker and CA9 as a hypoxic tumor cell marker. Tumor vessels (CD34; pink) decreased from the periphery to the central region. Conversely, CA9 expression in tumor cells (brown) increased from the periphery to the central region Purpose: This study aimed to identify novel hypoxia-inducible and prognostic markers in vivo from hypoxic tumor cells. Experimental Design: Using carbonic anhydrase 9 and CD34 as a guide for hypoxic tumor cells, laser capture microdissection was used to isolate colorectal cancer (CRC) liver metastases. The samples were analyzed by microarray analysis, in parallel with five CRC cell lines.
The CD34 + stem cells can self-renew as well as convert to a resting CD34 − phenotype. Alternatively, they may begin to differentiate, at which point they presumably lose their potential for self-renewal. These data suggest that CD34 may be a marker of activated stem cells, but not necessarily all stem cells CD34 staining is one of the important markers of tumor angiogenesis and microvascular density in HCC and is closely associated with HCC prognosis. 17, 24 In the current study, using liver thin-core biopsy specimens, we found that the sensitivity and specificity of CD34 expression in small HCC nodules (≤3 cm) were 94% and 89%, respectively As has been introduced above, CD34 + /CD38 − (Table 1) is the earliest documented stem cell marker combination in cancer and is still widely used to identify leukemic CSCs.In a seminal study, Dick and coworkers demonstrated that a small subpopulation of AML cells with the CD34 + /CD38 − cell surface phenotype was capable of producing a large number of colony-forming progenitors when. The use of CD34 as a marker for canine hematopoietic progenitor cells has been explored given the importance of canine models of autologous and allogeneic stem cell transplantations in studies of graft versus host disease, recombinant hematopoietic growth factors, and gene therapy. 10,14 CD34 has also been used as a marker for putative stem. These data show that CD34 is required for TPA-induced hair follicle stem cell activation and tumor formation in mice. AB - The cell surface marker CD34 marks mouse hair follicle bulge cells, which have attributes of stem cells, including quiescence and multipotency
Hematopoietic Stem Cell Marker (CD34, CD59, CD90 / Thy1, CD38, c-Kit) Antibody Panel - Huma CD34 is a glycosylated transmembrane protein and represents a well-known marker for primitive blood- and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial stem cells. Although the biological functions of CD34 are largely unknown, recent data suggest that CD34 is involved in maintenance of the progenitor cells in. WT1, the Wilms' tumor 1 gene, deserves particular interest because high WT1 expression levels in IM cells were found to be associated with signs of disease activity, such as the number of CD34 + cells in the PB or the severity score (Fig. 5C, 5D)
Creative diagnostics provides CD34 antibodies and elisa kits for science research use, feel free to contact us. > Cancer Cancer Stem Cells Cancer Stem Cell Markers > Cancer Cancer and Inflammation Leukocyte Adhesion and Extravasation > Cancer Hematologic Cancer Acute Myeloid Leukemia > Cancer Myeloid-derived Suppressor Cells. To determine the effectiveness of using CD34 as a marker, we used CD34 antibodies in our study of angiogenesis in NSCLC. In many solid tumors, including tumors in gastrointestinal cancer, cervical cancer, nasopharyngeal cancer, and breast cancer, profound angiogenic activity was found and the degree of angiogenesis was linked to tumor. CD34, when present, may prove equally helpful as a positive marker in cytology and in histologic preparations in the differential diagnosis of SFT. Cancer (Cancer Cytopathol) 1997;81:116-21. q 1997 American Cancer Society Among these stains are CD31,16-18 CD34,17-19 factor VIII,16-18 and VEGFR-3.16, 20 With increasing experience, CD31 expression has emerged as the gold standard for endothelial differentiation in angiosarcomas.17 Although CD31 and CD34 are considered markers of vascular differentiation, CD31 is not perfectly sensitive,21 while CD34 is not.
CD34 is a 115 kDa glycoprotein found on multipotent precursors, bone marrow stromal cells, embryonic fibroblasts, vascular endothelia, as well as some populations of mesenchymal stem cells, and tumor cell lines. CD34 is involved in the adhesion of stem cells to the bone marrow extracellular matrix or to stromal cells Angiogenesis is a proliferative process resulting in the development of new blood vessels from existing endothelial cells and is considered crucial for tumor growth and metastasis. Tumor angiogenesis can be quantified by microvascular density (MVD), which is evaluated in highly vascularized tumor areas (hot spots) by immunohistochemical assays using CD34 and CD31 pan-endothelial antibodies From the observation that the lesions were present in both pediatric and adult patients and that the tumor cells were negative for dermal dendritic marker Factor XIIIa, Kutzner and coauthors 6 believed the descriptive term of plaque-like CD34 + dermal fibroma was more appropriate than ML-DDH